Ra Pharmaceuticals to Present at the Jefferies 2016 Complement Therapeutics Summit

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Ra Pharmaceuticals, a clinical stage biopharmaceutical company focusing
on the development of next-generation therapeutics for diseases of
complement dysregulation and orphan indications defined by validated
biomarkers, today announced that Doug Treco, PhD, President and Chief
Executive Officer, will present at the Jefferies 2016 Complement
Therapeutics Summit on Tuesday, May 3, 2016 at 10:45 a.m. E.T. The
conference is being held at the Jefferies Conference Center in New York.

About Ra Pharmaceuticals

Ra Pharmaceuticals is a clinical stage biopharmaceutical company
focusing on the development of next-generation therapeutics for diseases
of complement dysregulation and orphan indications defined by validated
biomarkers. The Company’s proprietary Extreme Diversity™ peptide
chemistry platform delivers drugs with the diversity and specificity of
antibodies, coupled with the pharmacological properties of small
molecules. RA101495, the Company’s lead synthetic macrocyclic peptide
inhibitor of complement C5, is currently in Phase 1 development for the
treatment of paroxysmal nocturnal hemoglobinuria (PNH). For more
information, please visit: www.rapharma.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160426005429/en/